Equities research analysts expect BIO-TECHNE Corp (NASDAQ:TECH) to report earnings of $1.10 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for BIO-TECHNE’s earnings, with estimates ranging from $1.04 to $1.17. BIO-TECHNE reported earnings per share of $0.97 during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.4%. The company is scheduled to report its next earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that BIO-TECHNE will report full year earnings of $4.11 per share for the current year, with EPS estimates ranging from $3.98 to $4.36. For the next year, analysts anticipate that the business will post earnings of $4.54 per share, with EPS estimates ranging from $4.30 to $4.96. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover BIO-TECHNE.
BIO-TECHNE (NASDAQ:TECH) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.10. The firm had revenue of $154.15 million during the quarter, compared to analysts’ expectations of $145.93 million. BIO-TECHNE had a net margin of 19.17% and a return on equity of 14.39%. The firm’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.81 earnings per share.
A number of institutional investors and hedge funds have recently modified their holdings of the business. First Trust Advisors LP grew its position in BIO-TECHNE by 13.7% during the fourth quarter. First Trust Advisors LP now owns 410,991 shares of the biotechnology company’s stock worth $53,244,000 after buying an additional 49,470 shares during the period. New Mexico Educational Retirement Board acquired a new position in BIO-TECHNE during the fourth quarter worth about $1,201,000. Swiss National Bank grew its position in BIO-TECHNE by 1.9% during the fourth quarter. Swiss National Bank now owns 63,611 shares of the biotechnology company’s stock worth $8,241,000 after buying an additional 1,200 shares during the period. California Public Employees Retirement System grew its position in BIO-TECHNE by 5.5% during the fourth quarter. California Public Employees Retirement System now owns 75,930 shares of the biotechnology company’s stock worth $9,837,000 after buying an additional 3,937 shares during the period. Finally, Teacher Retirement System of Texas grew its position in BIO-TECHNE by 313.7% during the fourth quarter. Teacher Retirement System of Texas now owns 12,753 shares of the biotechnology company’s stock worth $1,652,000 after buying an additional 9,670 shares during the period. Institutional investors own 96.89% of the company’s stock.
BIO-TECHNE (TECH) traded down $4.49 during midday trading on Friday, reaching $131.96. 202,591 shares of the company traded hands, compared to its average volume of 185,318. The stock has a market capitalization of $5,160.79, a PE ratio of 44.06, a P/E/G ratio of 3.11 and a beta of 0.78. BIO-TECHNE has a 52-week low of $98.22 and a 52-week high of $143.64. The company has a quick ratio of 2.25, a current ratio of 3.10 and a debt-to-equity ratio of 0.36.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 2nd. Shareholders of record on Friday, February 16th will be given a dividend of $0.32 per share. The ex-dividend date is Thursday, February 15th. This represents a $1.28 annualized dividend and a yield of 0.97%. BIO-TECHNE’s payout ratio is currently 41.97%.
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.